Fair question. The p2 / p3 blended OSA trial will cost...

First 223 Last

Share
Profile

Follow
MickeyMantle536

933 Posts.

1446

06/12/22

22:11

Post #: 65185246
Share

Originally posted by SMT1994 ↑

Hi all,I have a question for the veteran IHL posters here.On page 25 of the Capital Raising Presentation, it says that "The company will be fully funded until 2025 post completion of this offer" as we will have $45m cash.However, in the Proactive interview posted above, Joel says at approximately 2:40 that 2 sites for phase 2 studies cost approximately $5m. Joel says that the plan is to establish 20 to 30 sites across US and europe for phase 3. Using these numbers available to us, my calculations indicate that this will cost approximately $50m to $75m i.e. more than the $45m we will have in the bank.Doesn't this contradict the statement that we are fully funded to 2025, given that we are going to need more funds to cover the cost of establishing these sites plus the costs of running our other medicinal trials parralell ?Not sure if I have overlooked something, but this is a little concerning to me. It would be very much appreciated if someone could help explain the discrepancy here or provide further clarification.Thanks so much!

Expand

Fair question.

The p2 / p3 blended OSA trial will cost significantly less than that, closer to $20m. It’s not a function of multiplying the number of sites by $2.5m, although I understand why you made that calculation.

The 2025 estimate is a genuine budget running all trials (refer page 26 of presentation) based on cash in bank plus R&D rebates where applicable.

Importantly the company can complete all this work regardless of market conditions in the next couple of years. That’s leadership.

IHL Price at posting: 20.0¢ Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

STX

Strike Energy secures $153 million for Perth Basin gas projects

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

BRX

Belararox delineates another porphyry in Argentina at Tambo South

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

GYG

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

FHE

Frontier Energy achieves key milestone for Waroona energy project